Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal
Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal · Investor's Business Daily

In This Article:

Biotech stock Neurogene collapsed Tuesday after a patient experienced a serious side effect in the company's Rett syndrome study.